Expansion of the Mendelian Disease Scanning Platform - for the fast, accurate, automated diagnosis of neuroendocrine tumours

点击翻译按钮获取中文摘要

40,000 people in the UK (c.200,000 in the US) are affected by a neuroendocrine tumour (NET). NETs are rare cancers that are hard to detect, and are often mistaken for other conditions. As a result patients face significant delays in reaching a diagnosis (median \>4 years from symptomatic onset). Late diagnosis affects patient prognosis (survival rate), costs the NHS (while patients go through many tests) and diminishes the effectiveness of treatments. Mendelian, a UK digital health company, has developed MendelScan, a technology that can scan electronic health records to detect patients who likely have a rare disease but have been missed by standard care. It is a Class 1 Medical device that uses pseudonymised data to protect patient privacy, while supporting NHS clinicians to offer world-leading care. Mendelian already works with the NHS and life sciences organisations to detect potentially undiagnosed patients with 30 rare diseases, and aims to find them paths to treatment, diagnosis or clinical trials. This grant will fund Mendelian's industrial research into NETs, with the purpose of expanding the MendelScan platform. If successful, this would lead to an ever greater value of Mendelian's technology: for healthcare providers and payers across the world (including the NHS); for patients who are sick but who lack a diagnosis; and for life sciences companies who seek to get patients early access to therapeutic technologies. Mendelian will aim to generate sufficient clinical and technology validation for MendelScan in NETs, and remains committed to the ethical, collaborative development of digital health technologies, to benefit patients around the world.